Hainan Huluwa Pharmaceutical Group Co Ltd (605199) — Capital Reinvestment Ratio

Latest as of September 2025: 0.21x

Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥44.34 Million) in capital expenditures (CN¥9.15 Million). See 605199 equity to assets ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.21x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥44.34 Million
CNY

Capital Expenditures

CN¥9.15 Million
CNY

Data as of

Sep 2025
Most recent filing

Hainan Huluwa Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Hainan Huluwa Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check how aggressively does Hainan Huluwa Pharmaceutical Group Co Lt reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. For live market cap and broader valuation context, see market value of Hainan Huluwa Pharmaceutical Group Co Lt.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.61x CN¥136.85 Million CN¥83.67 Million ▼ -96.5%
2023 17.32x CN¥28.25 Million CN¥489.20 Million ▲ +953.6%
2022 1.64x CN¥238.71 Million CN¥392.32 Million ▲ +22.4%
2021 1.34x CN¥102.48 Million CN¥137.62 Million ▼ -92.5%
2020 18.01x CN¥3.30 Million CN¥59.42 Million ▲ +4355.8%
2019 0.40x CN¥144.51 Million CN¥58.40 Million ▼ -82.4%
2018 2.29x CN¥31.80 Million CN¥72.82 Million ▲ +30.7%
2017 1.75x CN¥89.96 Million CN¥157.58 Million ▲ +177.6%
2016 0.63x CN¥64.96 Million CN¥40.99 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow